Merck Reports Strong Tulisokibart Data and Revenue Growth in 2026
Merck & Co. (ISIN US58933Y1055) announced positive results from its phase 2b study of tulisokibart on September 30, 2026, marking a significant clinical milestone. The study met both primary and key secondary endpoints in patients with moderate to severe hidradenitis suppurativa, expanding Merck's portfolio beyond oncology into inflammatory diseases. The news came amid a strong second quarter for the company, with revenue increasing 5.10% year over year to USD 16.61 billion, though net income reflected a loss of USD 1.34 billion due to business-development charges.
Analysts remain optimistic, with 16 rating Merck & Co. stock a Buy and 11 a Hold, according to MarketBeat on October 3, 2026. The consensus target price stands at USD 145.76. As of October 5, 2026, the stock was trading at EUR 128.74 on Lang & Schwarz, up 0.61% from the prior close of EUR 127.96. The company's market capitalization is USD 356.40 billion, with a 52-week range of USD 82.01 to USD 156.92.
Merck has raised and narrowed its full-year 2026 revenue guidance to USD 66.30 billion to USD 67.30 billion, with adjusted earnings per share guidance of USD 2.66 to USD 2.76. The company is set to discuss its third-quarter 2026 sales and earnings on a conference call scheduled for October 29, 2026. The positive tulisokibart data and strong revenue growth position Merck favorably, though earnings have been impacted by recent financial adjustments.